Back to search

Netherlands· NL-ca318b323cf2

EVOTAZ 300 mg/150 mg filmomhulde tabletten

A atazanavir and cobicistat product containing atazanavirsulfaat + cobicistat, registered in Netherlands by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 11 of our 19 countries.

ATC J05AR15

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEVOTAZ 300 mg/150 mg filmomhulde tabl…ATCJ05AR15REGISTER NO.NL-ca318b323cf2PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Atazanavir and cobicistat is registered in 11 of 19 countries.

Countries holding a registration under ATC J05AR15 (atazanavir and cobicistat), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose

Atazanavir and cobicistat · ATC J05AR15

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Spainprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ATAZANAVIRSULFAAT + COBICISTAT
Manufacturer
Bristol-Myers Squibb Pharma EEIG
Country
Netherlands (NL)
ATC code
J05AR15
ATC class
Atazanavir and cobicistat
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/15/1025

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4ade3e15-cc0c-46b9-ba7f-1f3a1759b05c
GET /v1/drugs/4ade3e15-cc0c-46b9-ba7f-1f3a1759b05c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/evotaz-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Atazanavir and cobicistat",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp115908",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "CROSPOVIDON (E 1202)",
    "GLYCEROLTRIACETAAT (E 1518)",
    "HYPROLOSE (E 463)",
    "HYPROMELLOSE (E 464)",
    "IJZEROXIDE ROOD  (E 172)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "SILICIUMDIOXIDE (E 551)",
    "STEARINEZUUR (E 570)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "ATAZANAVIRSULFAAT",
    "COBICISTAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2015/07/13",
  "procedure_number": "EMEA/H/C/003904",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/15/1025",
  "additional_monitoring": "N"
}

See everything about atazanavir and cobicistat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.